Scholars@Duke
William Schuyler Jones

William Schuyler Jones

Professor of Medicine
Medicine, Cardiology
schuyler.jones@duke.edu
Duke Box 3330, Durham, NC 27710
2400 Pratt Street, 7037, Durham, NC 27705

Selected Publications

Ethical Considerations for Informed Consent in Acute Myocardial Infarction Clinical Trials.

Journal Article Circ Cardiovasc Interv · May 27, 2025 Obtaining informed consent for clinical trial participation in acute myocardial infarction presents unique ethical and logistical challenges because of the patient distress, sedation, and the urgency of treatment. Traditional consent procedures often confl ... Full text Link to item Cite

Femoropopliteal Endovascular Intervention: A Review of the Current Landscape.

Journal Article Circ Cardiovasc Interv · May 2025 Superficial femoral artery disease poses significant challenges in patients with peripheral artery disease due to its unique anatomic and physiological characteristics. While conservative measures remain the initial approach for chronic, stable symptoms, e ... Full text Link to item Cite

Vascular Access and Management of Complications.

Journal Article Interv Cardiol Clin · April 2025 Vascular access requires a deliberate and thoughtful approach. Optimal femoral access involves understanding anatomic, fluoroscopic, and ultrasound principles. Combining all 3 approaches optimizes femoral access and minimizes complications, with ultrasound ... Full text Link to item Cite

2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Journal Article Circulation · April 1, 2025 Aim: The “2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes” incorporates new evidence since the “2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction” and the corresponding “20 ... Full text Cite

Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS.

Journal Article J Am Coll Cardiol · March 25, 2025 BACKGROUND: Limited data exist on the optimal antithrombotic strategy to minimize total bleeding and ischemic events for patients with recent acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) and atrial fibrillation (AF). OBJECTIVES ... Full text Link to item Cite

Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trial.

Journal Article Eur J Heart Fail · March 2025 AIMS: In the EMPACT-MI trial, empagliflozin reduced heart failure (HF) hospitalizations but not mortality in acute myocardial infarction (MI). Contemporary reports of clinical event rates with and without type 2 diabetes mellitus (T2DM) in acute MI trials ... Full text Link to item Cite

Pediatric Gastrointestinal Tract Outcomes During the Postacute Phase of COVID-19.

Journal Article JAMA Netw Open · February 3, 2025 IMPORTANCE: The profile of gastrointestinal (GI) tract outcomes associated with the postacute and chronic phases of COVID-19 in children and adolescents remains unclear. OBJECTIVE: To investigate the risks of GI tract symptoms and disorders during the post ... Full text Link to item Cite

Risk of Atherosclerotic Cardiovascular Disease After Chronic Obstructive Pulmonary Disease Hospitalization among Primary and Secondary Prevention Older Adults.

Journal Article J Am Heart Assoc · January 21, 2025 BACKGROUND: Meta-analyses have suggested that the risk of cardiovascular disease events is significantly higher after a chronic obstructive pulmonary disease (COPD) exacerbation, but the populations at highest risk have not been well characterized to date. ... Full text Link to item Cite

Asundexian versus Apixaban in Patients with Atrial Fibrillation.

Journal Article N Engl J Med · January 2, 2025 BACKGROUND: Stroke prevention with direct-acting oral anticoagulant agents in patients with atrial fibrillation confers a risk of bleeding and limits their use. Asundexian, an activated factor XI (XIa) inhibitor, is an oral anticoagulant that may prevent s ... Full text Link to item Cite

Description and toolkit for a research participant referral service.

Journal Article J Clin Transl Sci · 2025 The success of clinical research studies depends on effective recruitment and retention of study participants, yet only a small fraction of patients engage in research studies, even in academic health systems. Increasing awareness of research opportunities ... Full text Link to item Cite

Quantifying patients' preferences on tradeoffs between mortality risk and reduced need for target vessel revascularization for claudication.

Journal Article Vasc Med · December 2024 BACKGROUND: In 2019, the US Food and Drug Administration issued a warning that symptomatic relief from claudication using paclitaxel-coated devices might be associated with an increase in mortality over 5 years. We designed a discrete-choice experiment (DC ... Full text Link to item Cite

Risk of Atherosclerotic Cardiovascular Disease Hospitalizations after Chronic Obstructive Pulmonary Disease Hospitalization among Older Adults.

Journal Article Ann Am Thorac Soc · November 2024 Rationale: Meta-analyses have suggested the risk of cardiovascular disease (CVD) events is significantly higher after a chronic obstructive pulmonary disease (COPD) exacerbation. However, many of these studies have included a broad array of CVD events or h ... Full text Link to item Cite

Predictors and outcomes of intracranial hemorrhage in 58,000 patients with atrial fibrillation on oral anticoagulation: insights from COMBINE-AF

Conference European Heart Journal · October 28, 2024 AbstractBackgroundAmong anticoagulated patients with atrial fibrillation (AF), intracranial hemorrhage (ICH) is the leading cause of b ... Full text Cite

The Use of Cangrelor in Cardiogenic Shock: Insights from the CAMEO Registry.

Journal Article J Card Fail · October 2024 INTRODUCTION: Little is known about the use of cangrelor in patients with myocardial infarction (MI) presenting with cardiogenic shock (CS). METHODS: CAMEO (Cangrelor in Acute MI: Effectiveness and Outcomes) is a multicenter observational registry evaluati ... Full text Link to item Cite

Myocardial Revascularization in Heart Failure: A State-of-the-Art Review.

Journal Article J Card Fail · October 2024 Patients with heart failure (HF) and underlying coronary artery disease (CAD) have a substantially higher risk of mortality compared with those with HF from other causes. However, identifying individuals with HF for whom revascularization is likely to impr ... Full text Link to item Cite

Framework of the strengths and challenges of clinically integrated trials: An expert panel report.

Journal Article Am Heart J · September 2024 The limitations of the explanatory clinical trial framework include the high expense of implementing explanatory trials, restrictive entry criteria for participants, and redundant logistical processes. These limitations can result in slow evidence generati ... Full text Link to item Cite

Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.

Journal Article JAMA Cardiol · September 1, 2024 IMPORTANCE: Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality in the US. Although aspirin is recommended for secondary prevention of ASCVD, there was no difference in safety and effectiveness of aspirin dos ... Full text Link to item Cite

Contribution of Clinical Trial Event Data by Data Source: A Prespecified Analysis of the ADAPTABLE Randomized Clinical Trial.

Journal Article JAMA Cardiol · September 1, 2024 IMPORTANCE: Pragmatic randomized clinical trials (RCTs) often use multiple data sources to examine clinical events, but the relative contribution of data sources to clinical end-point rates is understudied. OBJECTIVE: To assess the contribution of data sou ... Full text Link to item Cite

In reply.

Journal Article Ann Emerg Med · September 2024 Full text Link to item Cite

Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.

Journal Article J Am Coll Cardiol · August 20, 2024 BACKGROUND: Emerging data suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve kidney outcomes for people with type 2 diabetes (T2D). Direct comparisons of the kidney and cardiovascular effectiveness of GLP-1 RA with sodium-glucose co ... Full text Open Access Link to item Cite

Development and Validation of a Natural Language Processing Model to Identify Low-Risk Pulmonary Embolism in Real Time to Facilitate Safe Outpatient Management.

Journal Article Ann Emerg Med · August 2024 STUDY OBJECTIVE: This study aimed to (1) develop and validate a natural language processing model to identify the presence of pulmonary embolism (PE) based on real-time radiology reports and (2) identify low-risk PE patients based on previously validated r ... Full text Link to item Cite

Medication-Induced Weight Change Across Common Antidepressant Treatments : A Target Trial Emulation Study.

Journal Article Ann Intern Med · August 2024 BACKGROUND: Antidepressants are among the most commonly prescribed medications, but evidence on comparative weight change for specific first-line treatments is limited. OBJECTIVE: To compare weight change across common first-line antidepressant treatments ... Full text Link to item Cite

Impact of aspirin dose according to race in secondary prevention of atherosclerotic cardiovascular disease: a secondary analysis of the ADAPTABLE randomised controlled trial.

Journal Article BMJ open · August 2024 ObjectivesTo evaluate whether the effectiveness and safety of low (81 mg daily) versus high-dose (325 mg daily) aspirin is consistent across races among patients with established atherosclerotic cardiovascular disease (ASCVD).DesignA seco ... Full text Cite

Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial.

Journal Article Eur Heart J Cardiovasc Pharmacother · July 16, 2024 AIMS: Large outcome trials have demonstrated cardiovascular benefits of selected glucagon-like peptide-1 (GLP-1) receptor agonists. We examined coronary disease outcomes in the Harmony Outcomes trial of the GLP-1 receptor agonist albiglutide. METHODS AND R ... Full text Link to item Cite

Diagnostic Performance of Coronary Angiography Derived Computational Fractional Flow Reserve.

Journal Article J Am Heart Assoc · July 2, 2024 BACKGROUND: Computational fluid dynamics can compute fractional flow reserve (FFR) accurately. However, existing models are limited by either the intravascular hemodynamic phenomarkers that can be captured or the fidelity of geometries that can be modeled. ... Full text Open Access Link to item Cite

Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis.

Journal Article Lancet Diabetes Endocrinol · July 2024 BACKGROUND: Sodium-glucose co-transporter-2 (SGLT2) inhibitors have been studied in patients with heart failure, type 2 diabetes, chronic kidney disease, atherosclerotic cardiovascular disease, and acute myocardial infarction. Individual trials were powere ... Full text Link to item Cite

Kidney and Cardiovascular Effectiveness of Empagliflozin Compared With Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes.

Journal Article Am J Cardiol · June 15, 2024 Placebo-controlled trials of sodium-glucose co-transporter-2 inhibitors demonstrate kidney and cardiovascular benefits for patients with type 2 diabetes and chronic kidney disease (CKD). We used real-world data to compare the kidney and cardiovascular effe ... Full text Open Access Link to item Cite

Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction.

Journal Article J Am Coll Cardiol · June 11, 2024 BACKGROUND: Empagliflozin reduces the risk of heart failure (HF) hospitalizations but not all-cause mortality when started within 14 days of acute myocardial infarction (AMI). OBJECTIVES: This study sought to evaluate the association of left ventricular ej ... Full text Link to item Cite

2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Journal Article Circulation · June 11, 2024 AIM: The "2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease" provides recommendations to guide clinicians in the treatment of patients with lower extremity peripheral artery dis ... Full text Link to item Cite

Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes.

Journal Article JAMA Netw Open · June 3, 2024 IMPORTANCE: Chronic kidney disease (CKD) is an often-asymptomatic complication of type 2 diabetes (T2D) that requires annual screening to diagnose. Patient-level factors linked to inadequate screening and treatment can inform implementation strategies to f ... Full text Open Access Link to item Cite

Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial.

Journal Article Circulation · May 21, 2024 BACKGROUND: Empagliflozin reduces the risk of heart failure (HF) events in patients with type 2 diabetes at high cardiovascular risk, chronic kidney disease, or prevalent HF irrespective of ejection fraction. Whereas the EMPACT-MI trial (Effect of Empaglif ... Full text Link to item Cite

Case Volumes and Outcomes Among Early-Career Interventional Cardiologists in the United States.

Journal Article J Am Coll Cardiol · May 21, 2024 BACKGROUND: Little is known about the procedural characteristics, case volumes, and mortality rates for early- vs non-early-career interventional cardiologists in the United States. OBJECTIVES: This study examined operator-level data for patients who under ... Full text Link to item Cite

Outcomes of peripheral artery disease and polyvascular disease in patients with end-stage kidney disease.

Journal Article Journal of vascular surgery · May 2024 ObjectivePatients with peripheral artery disease (PAD) and end-stage kidney disease are a high-risk population, and concomitant atherosclerosis in coronary arteries (CAD) or cerebral arteries (CVD) is common. The aim of the study was to assess lon ... Full text Cite

Comparative analysis of hospitalization risk for incident heart failure in non-Hispanic Black versus non-Hispanic White individuals with type 2 diabetes on empagliflozin (Empa-AA): Insights from real-world data.

Journal Article Diabetes Obes Metab · May 2024 AIM: There are limited data to evaluate hospitalization for heart failure (hHF) in non-Hispanic Black (hereafter Black) or non-Hispanic White (hereafter White) individuals without previous hHF. Our goal was to evaluate the risk of hHF among Black versus Wh ... Full text Link to item Cite

Empagliflozin after Acute Myocardial Infarction.

Journal Article N Engl J Med · April 25, 2024 BACKGROUND: Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes who are at high cardiovascular risk, and patients with chronic kidney disease. The safety and efficacy of empagliflozin in patients who ... Full text Link to item Cite

The effect of relative hypotension on 30-day mortality in older people receiving emergency care.

Journal Article Intern Emerg Med · April 2024 Research has observed increased mortality among older people attending the emergency department (ED) who had systolic pressure > 7 mmHg lower than baseline primary care values. This study aimed to (1) assess feasibility of identifying this 'relative hypote ... Full text Link to item Cite

Shorter Dual Antiplatelet Therapy for Older Adults After Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis.

Journal Article JAMA Netw Open · March 4, 2024 IMPORTANCE: The optimal duration of dual antiplatelet therapy (DAPT) for older adults after percutaneous coronary intervention (PCI) is uncertain because they are simultaneously at higher risk for both ischemic and bleeding events. OBJECTIVE: To investigat ... Full text Link to item Cite

Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease.

Journal Article J Am Heart Assoc · February 20, 2024 BACKGROUND: In patients with atherosclerotic cardiovascular disease, increasing age is concurrently associated with higher risks of ischemic and bleeding events. The objectives are to determine the impact of aspirin dose on clinical outcomes according to a ... Full text Link to item Cite

Risk of Bleeding Among Cangrelor-Treated Patients Administered Upstream P2Y12 Inhibitor Therapy: The CAMEO Registry.

Conference J Soc Cardiovasc Angiogr Interv · February 2024 BACKGROUND: Little is known about the bleeding risk associated with cangrelor use in patients with myocardial infarction (MI) who are exposed to an oral P2Y12 inhibitor before coronary angiography. METHODS: Cangrelor in Acute MI: Effectiveness and Outcomes ... Full text Link to item Cite

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Journal Article J Am Coll Cardiol · January 2, 2024 AIM: The "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation" provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation. METHODS: A comprehensive literature search ... Full text Link to item Cite

Initial Management Strategy and Long-Term Outcomes in 186 Cases of Spontaneous Coronary Artery Dissection.

Journal Article Semin Thorac Cardiovasc Surg · 2024 Spontaneous coronary artery dissection (SCAD) is a rare but important nonatherosclerotic cause of acute coronary syndrome. Indications for revascularization and long-term outcomes of SCAD remain areas of active investigation. We report our experience with ... Full text Link to item Cite

Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial.

Journal Article Diabetes Care · January 1, 2024 OBJECTIVE: Patients with diabetes mellitus (DM) and concomitant atherosclerotic cardiovascular disease (ASCVD) must be on the most effective dose of aspirin to mitigate risk of future adverse cardiovascular events. RESEARCH DESIGN AND METHODS: ADAPTABLE, a ... Full text Link to item Cite

Excess burden of respiratory and abdominal conditions following COVID-19 infections during the ancestral and Delta variant periods in the United States: An EHR-based cohort study from the RECOVER program.

Journal Article PLoS One · 2024 IMPORTANCE: The frequency and characteristics of post-acute sequelae of SARS-CoV-2 infection (PASC) may vary by SARS-CoV-2 variant. OBJECTIVE: To characterize PASC-related conditions among individuals likely infected by the ancestral strain in 2020 and ind ... Full text Link to item Cite

Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD.

Conference Circulation · December 12, 2023 BACKGROUND: Rivaroxaban plus aspirin compared with aspirin alone reduced major cardiac and ischemic limb events after lower extremity revascularization (LER) in the VOYAGER PAD (Vascular Outcomes Study of ASA Along With Rivaroxaban in Endovascular or Surgi ... Full text Link to item Cite

Morbidity and Mortality Associated With Heart Failure in Acute Coronary Syndrome: A Pooled Analysis of 4 Clinical Trials.

Journal Article J Card Fail · December 2023 BACKGROUND: Heart failure (HF) may complicate acute coronary syndrome (ACS) and is associated with a high burden of short- and long-term morbidity and mortality. Only limited data regarding future ischemic events and rehospitalization are available for pat ... Full text Link to item Cite

Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications.

Journal Article J Am Coll Cardiol · November 7, 2023 BACKGROUND: Renal denervation (RDN) reduces blood pressure (BP) in patients with uncontrolled hypertension in the absence of antihypertensive medications. OBJECTIVES: This trial assessed the safety and efficacy of RDN in the presence of antihypertensive me ... Full text Link to item Cite

2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.

Journal Article J Thorac Cardiovasc Surg · November 2023 AIM: The "2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease" provides recommendations to guide clinicians in the diagnosis, genetic evaluation and family screening, medical therapy, endovascular and surgical treatment, and long-term ... Full text Link to item Cite

Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.

Journal Article JAMA Cardiol · November 1, 2023 IMPORTANCE: Clinicians recommend enteric-coated aspirin to decrease gastrointestinal bleeding in secondary prevention of coronary artery disease even though studies suggest platelet inhibition is decreased with enteric-coated vs uncoated aspirin formulatio ... Full text Link to item Cite

Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery.

Journal Article Circulation · October 24, 2023 BACKGROUND: Right ventricular failure (RVF) is a leading driver of morbidity and death after major cardiac surgery for advanced heart failure, including orthotopic heart transplantation and left ventricular assist device implantation. Inhaled pulmonary-sel ... Full text Open Access Link to item Cite

Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors.

Journal Article J Am Heart Assoc · October 17, 2023 Background The ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) was a large, pragmatic, randomized controlled trial that found no difference between high- versus low-dose aspirin for secondary prevention of ... Full text Link to item Cite

Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE.

Journal Article Am Heart J · October 2023 BACKGROUND: Among patients with established cardiovascular disease, the ADAPTABLE trial found no significant differences in cardiovascular events and bleeding rates between 81 mg and 325 mg of aspirin (ASA) daily. In this secondary analysis from the ADAPTA ... Full text Link to item Cite

Baseline characteristics of patients enrolled in the EMPACT-MI trial.

Journal Article Eur J Heart Fail · September 2023 AIMS: Empagliflozin has been shown to reduce the risk of adverse cardiovascular outcomes in patients with type 2 diabetes and in those with heart failure. The impact of empagliflozin in post-acute myocardial infarction (AMI) patients is unknown. METHODS AN ... Full text Link to item Cite

Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial.

Journal Article J Card Fail · August 2023 BACKGROUND: Hospitalization due to heart failure (HFH) is a major source of morbidity, consumes significant economic resources and is a key endpoint in HF clinical trials. HFH events vary in severity and implications, but they are typically considered equi ... Full text Link to item Cite

Internet Versus Noninternet Participation in a Decentralized Clinical Trial: Lessons From the ADAPTABLE Study.

Journal Article J Am Heart Assoc · July 4, 2023 Background Internet-based participation has the potential to enhance pragmatic and decentralized trials, where representative study populations and generalizability to clinical practice are key. We aimed to study the differences between internet and nonint ... Full text Link to item Cite

Association of race and in-hospital outcomes following acute pulmonary embolism: A retrospective cohort study.

Journal Article Clin Cardiol · July 2023 BACKGROUND: Racial disparities in health care are well established, with Black patients frequently experiencing the most significant consequences of this inequality. Acute pulmonary embolism (PE) is increasing in incidence and an important cause of morbidi ... Full text Link to item Cite

Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes.

Conference Am J Prev Cardiol · June 2023 OBJECTIVE: Elevated lipoprotein(a) [Lp(a)] is associated with atherosclerotic cardiovascular disease, yet little is known about Lp(a) testing patterns in real-world practice. The objective of this analysis was to determine how Lp(a) testing is used in clin ... Full text Link to item Cite

Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale.

Journal Article J Am Geriatr Soc · June 2023 Whether initiation of statins could increase survival free of dementia and disability in adults aged ≥75 years is unknown. PREVENTABLE, a double-blind, placebo-controlled randomized pragmatic clinical trial, will compare high-intensity statin therapy (ator ... Full text Link to item Cite

Does early detection of atrial fibrillation reduce the risk of thromboembolic events? Rationale and design of the Heartline study.

Journal Article Am Heart J · May 2023 BACKGROUND: The impact of using direct-to-consumer wearable devices as a means to timely detect atrial fibrillation (AF) and to improve clinical outcomes is unknown. METHODS: Heartline is a pragmatic, randomized, and decentralized application-based trial o ... Full text Link to item Cite

Evaluation of weight change and cardiometabolic risk factors in a real-world population of US adults with overweight or obesity.

Journal Article Prev Med · May 2023 Whether individuals in real-world settings are able to lose weight and improve cardiometabolic risk factors over time is unclear. We aimed to determine the management of and degree of body weight change over 2 years among individuals with overweight or obe ... Full text Link to item Cite

Long-term outcomes of peripheral atherectomy for femoropopliteal endovascular interventions.

Journal Article EuroIntervention · April 3, 2023 BACKGROUND: The use of atherectomy during peripheral endovascular interventions (PVI) has increased dramatically, but data regarding its safety and effectiveness are lacking.  Aims: This study sought to determine the long-term safety of atherectomy in cont ... Full text Link to item Cite

Outcomes among patients with peripheral artery disease in the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study.

Journal Article Vasc Med · April 2023 BACKGROUND: We aimed to understand the effects of aspirin dose on outcomes in patients with peripheral artery disease (PAD) as well as their participation in a pragmatic randomized controlled trial. METHODS: In a subanalysis of the Aspirin Dosing: A Patien ... Full text Link to item Cite

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists.

Journal Article Am J Prev Cardiol · March 2023 Cardiovascular disease remains one of the most prominent global health problems and has been demonstrated to disproportionally affect certain communities. Despite an increasing collective effort to improve health inequalities, a multitude of disparities co ... Full text Open Access Link to item Cite

Importance of patient engagement in the conduct of pragmatic multicenter randomized controlled trials: The ADAPTABLE experience.

Journal Article Clin Trials · February 2023 BACKGROUND/AIMS: Actively engaging patient partners in the conduct of trials is crucial to ensure the studies answer genuine, patient-centered, unmet clinical needs, and to facilitate participant recruitment and retention. The aim of this article is to dem ... Full text Link to item Cite

Timing of sedation and patient-reported pain outcomes during cardiac catheterization: Results from the UNTAP-intervention study.

Journal Article Catheter Cardiovasc Interv · January 14, 2023 BACKGROUND: Invasive cardiac catheterization (CC) temporarily increases pain, discomfort, and anxiety. Procedural sedation is deployed to mitigate these symptoms, though practice varies. Research evaluating peri-procedural patient-reported outcomes is lack ... Full text Link to item Cite

Initial Thoracic Endovascular Aortic Repair vs Medical Therapy for Acute Uncomplicated Type B Aortic Dissection.

Journal Article JAMA Cardiol · January 1, 2023 IMPORTANCE: Thoracic endovascular aortic repair (TEVAR) has increasingly been used for uncomplicated type B aortic dissection (uTBAD) despite limited supporting data. OBJECTIVE: To assess whether initial TEVAR following uTBAD is associated with reduced mor ... Full text Link to item Cite

TRENDS AND OUTCOMES IN AORTIC STENOSIS COMPLICATED BY SHOCK

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · 2023 Cite

2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.

Journal Article Circulation · December 13, 2022 AIM: The "2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease" provides recommendations to guide clinicians in the diagnosis, genetic evaluation and family screening, medical therapy, endovascular and surgical treatment, and long-term ... Full text Link to item Cite

2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

Journal Article Journal of the American College of Cardiology · December 13, 2022 Aim: The “2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease” provides recommendations to guide clinicians in the diagnosis, genetic evaluation and family screening, medical therapy, endovascular and surgical treatment, and long-term ... Full text Cite

Concordance Between Patient-Reported Health Data and Electronic Health Data in the ADAPTABLE Trial.

Journal Article JAMA Cardiol · December 1, 2022 IMPORTANCE: Patient-reported health data can facilitate clinical event capture in pragmatic clinical trials. However, few data are available on the fitness for use of patient-reported data in large-scale health research. OBJECTIVE: To evaluate the concorda ... Full text Link to item Cite

Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial.

Journal Article Am Heart J · November 2022 BACKGROUND: Patients with acute myocardial infarction (MI) are at risk for developing heart failure (HF) and subsequently are at an increased risk of mortality. Sodium-glucose cotransporter-2 inhibitors have been proven to improve outcomes in patients with ... Full text Link to item Cite

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.

Journal Article Circulation · October 18, 2022 BACKGROUND: Oral activated factor XI (FXIa) inhibitors may modulate coagulation to prevent thromboembolic events without substantially increasing bleeding. We explored the pharmacodynamics, safety, and efficacy of the oral FXIa inhibitor asundexian for sec ... Full text Link to item Cite

Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction: A Review.

Journal Article JAMA Cardiol · October 1, 2022 IMPORTANCE: Despite advances in cardiac care, patients remain at a high risk of death and the development of heart failure (HF) following myocardial infarction (MI). These risks are highest in patients with reduced ejection fraction (EF) or signs of HF imm ... Full text Link to item Cite

Assessment of the burden of disease for patients with peripheral artery disease undergoing revascularization in England.

Journal Article Vasc Med · October 2022 Background: Symptoms, severity, and acuteness of peripheral artery disease (PAD) are major determinants of severe limb symptoms, subsequent risk of cardiovascular events, and mortality. Lower-extremity revascularization (LER) is a key option to relieve sym ... Full text Link to item Cite

In-hospital outcomes and readmission in older adults treated with percutaneous coronary intervention for stable ischemic heart disease.

Journal Article J Geriatr Cardiol · September 28, 2022 BACKGROUND: Percutaneous coronary intervention (PCI) for stable ischemic heart disease (SIHD) in older adults requires a meticulous assessment of procedural risks and benefits, but contemporary data on outcomes in this population is lacking. Therefore, we ... Full text Link to item Cite

Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials).

Journal Article Am J Cardiol · September 1, 2022 Patients with acute coronary syndrome (ACS) are at risk for recurrent adverse events, and multiple reports suggest that this risk is increased in patients with concomitant diabetes mellitus (DM) and peripheral artery disease (PAD). The aim of this article ... Full text Link to item Cite

Atrial branch coronary artery stenosis as a mechanism for atrial fibrillation.

Journal Article Heart Rhythm · August 2022 BACKGROUND: The etiology of atrial fibrillation (AF) is multifactorial and incompletely understood. OBJECTIVE: The purpose of this study was to evaluate the association between coronary artery disease (CAD) affecting atrial tissue and AF. METHODS: Patients ... Full text Link to item Cite

Impact of risk factor control on peripheral artery disease outcomes and health disparities.

Journal Article Vasc Med · August 2022 BACKGROUND: Peripheral artery disease (PAD) is associated with modifiable atherosclerotic risk factors like hypertension, diabetes, hyperlipidemia, and smoking. However, the effect of risk factor control on outcomes and disparities in achieving control is ... Full text Link to item Cite

Cardiovascular and Limb Events Following Endovascular Revascularization Among Patients ≥65 Years Old: An American College of Cardiology PVI Registry Analysis.

Journal Article J Am Heart Assoc · June 20, 2022 Background We aimed to characterize the occurrence of major adverse cardiovascular and limb events (MACE and MALE) among patients with peripheral artery disease (PAD) undergoing peripheral vascular intervention (PVI), as well as associated factors in patie ... Full text Link to item Cite

Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease.

Journal Article J Am Heart Assoc · June 7, 2022 Background Peripheral artery disease (PAD) is associated with heightened risk for major adverse cardiovascular and limb events, but data on the burden of risk for total (first and potentially subsequent) events, and the association with polyvascular diseas ... Full text Link to item Cite

Iterative approaches to the use of electronic health records data for large pragmatic studies.

Journal Article Contemp Clin Trials · June 2022 Randomized controlled trials (RCT) are the gold standard for evaluating the effectiveness and safety of interventions and treatments, yet traditional clinical trials have relied on cumbersome and redundant processes such as electronic data entry which invo ... Full text Link to item Cite

Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome.

Journal Article JACC Heart Fail · June 2022 Acute coronary syndrome (ACS) is frequently complicated by evidence of heart failure (HF). Those at highest risk for acute decompensated HF in the setting of ACS (ACS-HF) are older, female, and have preexisting heart disease, type 2 diabetes mellitus, hype ... Full text Link to item Cite

Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction: JACC Review Topic of the Week.

Journal Article J Am Coll Cardiol · May 24, 2022 Sodium glucose cotransporter-2 (SGLT2) inhibitors improve cardiorenal outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and chronic heart failure. SGLT2 inhibitors also reduce the risk of cardiovascular mortality and hospitalizati ... Full text Link to item Cite

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.

Journal Article J Card Fail · May 2022 AIM: The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" replaces the "2013 ACCF/AHA Guideline for the Management of Heart Failure" and the "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failu ... Full text Link to item Cite

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.

Journal Article Lancet · April 9, 2022 BACKGROUND: Direct-acting oral anticoagulant use for stroke prevention in atrial fibrillation is limited by bleeding concerns. Asundexian, a novel, oral small molecule activated coagulation factor XIa (FXIa) inhibitor, might reduce thrombosis with minimal ... Full text Link to item Cite

Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions - proceedings from the CEC Summit 2018.

Journal Article Am Heart J · April 2022 IMPORTANCE: Clinical events adjudication is pivotal for generating consistent and comparable evidence in clinical trials. The methodology of event adjudication is evolving, but research is needed to develop best practices and spur innovation. OBSERVATIONS: ... Full text Link to item Cite

The challenges of data safety monitoring for a pragmatic study: Lessons from the ADAPTABLE study.

Journal Article Contemp Clin Trials · April 2022 Data monitoring committees (DMCs) play a critical role in protecting the safety of participants and integrity of clinical studies. While there are well-established DMC guidelines for traditional, randomized controlled trials, the clinical trial community i ... Full text Link to item Cite

World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial.

Journal Article Vasc Med · February 2022 Regional variations exist in the epidemiology of peripheral artery disease (PAD), in comorbidities, use of secondary prevention, and outcomes. Large studies of these variations in worldwide populations are rare. The EUCLID (Examining Use of tiCagreLor In p ... Full text Open Access Link to item Cite

Clinician Specialty, Access to Care, and Outcomes Among Patients with Peripheral Artery Disease.

Journal Article Am J Med · February 2022 BACKGROUND: Understanding the relationship between patterns of peripheral artery disease and outcomes is an essential step toward improving care and outcomes. We hypothesized that clinician specialty would be associated with occurrence of major adverse vas ... Full text Link to item Cite

Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial.

Journal Article J Vasc Surg · February 2022 OBJECTIVE: Amputation remains a frequent and feared outcome in patients with peripheral artery disease (PAD). Although typically characterized as major or minor on the extent of tissue loss, the etiologies and outcomes after amputation by extent are not we ... Full text Link to item Cite

2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Journal Article Journal of the American College of Cardiology · January 18, 2022 Aim: The guideline for coronary artery revascularization replaces the 2011 coronary artery bypass graft surgery and the 2011 and 2015 percutaneous coronary intervention guidelines, providing a patient-centric approach to guide clinicians in the treatment o ... Full text Cite

CLASSIFICATION AND IMPLICATIONS OF HEART FAILURE EVENTS FROM THE VICTORIA TRIAL

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · 2022 Cite

Understanding Study Drug Discontinuation Through EUCLID.

Journal Article Front Cardiovasc Med · 2022 INTRODUCTION: Disparities in the care and outcomes of peripheral artery disease (PAD) have been well-established. In part this is due to disparities in enrollment of PAD trial cohorts. However, less attention has been paid to non-random protocol non-adhere ... Full text Link to item Cite

Rural-urban outcome differences associated with COVID-19 hospitalizations in North Carolina.

Journal Article PLoS One · 2022 People living in rural regions in the United States face more health challenges than their non-rural counterparts which could put them at additional risks during the COVID-19 pandemic. Few studies have examined if rurality is associated with additional mor ... Full text Link to item Cite

Predictors of adverse outcome in the first and second waves of the COVID-19 pandemic: results from a UK centre

Journal Article Therapeutic Advances in Infectious Disease · January 1, 2022 Background/Aims: Data concerning differences in demographics/disease severity between the first and second waves of COVID-19 are limited. We aimed to examine prognosis in patients presenting to hospital with COVID-19 amongst different ethnic groups between ... Full text Cite

Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial.

Journal Article Vasc Med · December 2021 Patients with chronic kidney disease may develop new or more severe anemia when treated with antiplatelet agents due to blood loss in conjunction with impaired erythropoiesis. Because anemia independently predicts limb amputation and mortality among patien ... Full text Link to item Cite

Younger patients with chronic limb threatening ischemia face more frequent amputations.

Journal Article Am Heart J · December 2021 INTRODUCTION: Amputations among younger patients with chronic limb threatening ischemia (CLTI) may carry higher personal and societal costs, but younger patients are often not included in CLTI research because of dataset limitations. We aimed to characteri ... Full text Link to item Cite

Cardiovascular risk and outcomes in symptomatic patients with suspected coronary artery disease and non coronary vascular disease: A report from the PROMISE trial.

Journal Article Am Heart J · December 2021 BACKGROUND: Non-coronary vascular disease (NCVD) is associated with adverse cardiovascular events. Little is known about physician risk assessment, prevalence of coronary artery disease (CAD), cardiac catheterization, and the performance of the atheroscler ... Full text Link to item Cite

Development and validation of a predictive model for bleeding after peripheral vascular intervention: A report from the National Cardiovascular Data Registry Peripheral Vascular Interventions Registry.

Journal Article Catheter Cardiovasc Interv · December 1, 2021 OBJECTIVES: To develop a model to predict risk of in-hospital bleeding following endovascular peripheral vascular intervention. BACKGROUND: Peri-procedural bleeding is a common, potentially preventable complication of catheter-based peripheral vascular pro ... Full text Link to item Cite

Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial.

Journal Article Atherosclerosis · December 2021 BACKGROUND AND AIMS: Polyvascular disease is an independent predictor of major adverse cardiovascular events (MACE). The relationship between the number of diseased arterial beds and MACE is unknown. How MACE risk changes in individuals with type 2 diabete ... Full text Link to item Cite

Validation of Cardiovascular End Points Ascertainment Leveraging Multisource Electronic Health Records Harmonized Into a Common Data Model in the ADAPTABLE Randomized Clinical Trial.

Journal Article Circ Cardiovasc Qual Outcomes · December 2021 BACKGROUND: The ADAPTABLE trial (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) is the first randomized trial conducted within the National Patient-Centered Clinical Research Network to use the electronic health rec ... Full text Link to item Cite

Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week.

Journal Article J Am Coll Cardiol · October 12, 2021 Patients undergoing early surgery after coronary stent implantation are at increased risk for mortality from ischemic and hemorrhagic complications. The optimal antiplatelet strategy in patients who cannot discontinue dual antiplatelet therapy (DAPT) befor ... Full text Link to item Cite

Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial.

Journal Article Diabet Med · October 2021 AIMS: Although models exist to predict amputation among people with type 2 diabetes with foot ulceration or infection, we aimed to develop a prediction model for a broader range of major adverse limb events (MALE)-including gangrene, revascularization and ... Full text Link to item Cite

The association of healthcare disparities and patient-specific factors on clinical outcomes in peripheral artery disease.

Journal Article Am Heart J · September 2021 BACKGROUND: PAD increases the risk of cardiovascular mortality and limb loss, and disparities in treatment and outcomes have been described. However, the association of patient-specific characteristics with variation in outcomes is less well known. METHODS ... Full text Link to item Cite

Aspirin Dosing in Cardiovascular Disease. Reply.

Journal Article N Engl J Med · August 19, 2021 Full text Link to item Cite

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.

Journal Article J Am Coll Cardiol · August 3, 2021 BACKGROUND: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is unce ... Full text Link to item Cite

Clinician engagement in the ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) trial.

Journal Article Clin Trials · August 2021 BACKGROUND: ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) is a pragmatic clinical trial examining high-dose versus low-dose aspirin among patients with cardiovascular disease. ADAPTABLE is leveraging nov ... Full text Link to item Cite

National trends in repair for type B aortic dissection.

Journal Article Clin Cardiol · August 2021 BACKGROUND: Thoracic endovascular aortic repair (TEVAR) first gained in popularity for repair of type B aortic dissections (TBADs) in the early 2000's. We aimed to describe patients undergoing open repair, TEVAR, and no repair and analyze factors associate ... Full text Link to item Cite

Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials.

Journal Article JAMA Netw Open · July 1, 2021 IMPORTANCE: Randomized clinical trials (RCTs) are critical in advancing patient care, yet conducting such large-scale trials requires tremendous resources and coordination. Clinical site start-up performance metrics can provide insight into opportunities f ... Full text Link to item Cite

Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID.

Journal Article J Am Heart Assoc · June 15, 2021 Background Peripheral artery disease (PAD) and heart failure (HF) are each independently associated with poor outcomes. Risk factors associated with new-onset HF in patients with primary PAD are unknown. Furthermore, how the presence of HF is associated wi ... Full text Link to item Cite

Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease.

Journal Article Am J Cardiol · June 1, 2021 To address literature gaps on treatment with real-world evidence, this study compared effectiveness, safety, and cost outcomes in NVAF patients with coronary or peripheral artery disease (CAD, PAD) prescribed apixaban versus other oral anticoagulants. NVAF ... Full text Link to item Cite

Does the Clinical Frailty Scale at Triage Predict Outcomes From Emergency Care for Older People?

Journal Article Ann Emerg Med · June 2021 STUDY OBJECTIVE: We determine whether the Clinical Frailty Scale applied at emergency department (ED) triage is associated with important service- and patient-related outcomes. METHODS: We undertook a single-center, retrospective cohort study examining hos ... Full text Link to item Cite

Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.

Journal Article N Engl J Med · May 27, 2021 BACKGROUND: The appropriate dose of aspirin to lower the risk of death, myocardial infarction, and stroke and to minimize major bleeding in patients with established atherosclerotic cardiovascular disease is a subject of controversy. METHODS: Using an open ... Full text Link to item Cite

Use of hospital resources in the care of patients with intermediate risk pulmonary embolism.

Journal Article Eur Heart J Acute Cardiovasc Care · May 11, 2021 BACKGROUND: Risk stratification and management of hemodynamically stable pulmonary embolism remains challenging. Professional societies have published stratification schemes, but little is known about the management of patients with intermediate risk pulmo ... Full text Link to item Cite

Registry Assessment of Peripheral Interventional Devices objective performance goals for superficial femoral and popliteal artery peripheral vascular interventions.

Journal Article J Vasc Surg · May 2021 BACKGROUND: The Superficial Femoral Artery-Popliteal EvidencE Development Study Group developed contemporary objective performance goals (OPGs) for peripheral vascular interventions (PVI) for superficial femoral artery (SFA)-popliteal artery disease using ... Full text Link to item Cite

The Role for Combined Antithrombotic Therapy With Platelet and Coagulation Inhibition After Lower Extremity Revascularization.

Journal Article JACC Cardiovasc Interv · April 12, 2021 Evidence for antithrombotic treatment following lower extremity revascularization (LER) for peripheral artery disease (PAD) is limited, leading to weak and conflicting guideline recommendations and heterogeneous practice patterns. This variability in post- ... Full text Link to item Cite

Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis.

Journal Article Am Heart J · March 2021 BACKGROUND: The connection between paclitaxel-coated devices (PCD) use during peripheral vascular interventions (PVI) and mortality is debated. We aimed to analyze patterns of PCD use and the safety and effectiveness of PCD use in the superficial femoral a ... Full text Link to item Cite

Comparing associations between frailty and mortality in hospitalised older adults with or without COVID-19 infection: a retrospective observational study using electronic health records.

Journal Article Age Ageing · February 26, 2021 BACKGROUND: The aim of this study was to describe outcomes in hospitalised older people with different levels of frailty and COVID-19 infection. METHODS: We undertook a single-centre, retrospective cohort study examining COVID-19-related mortality using el ... Full text Link to item Cite

Clinical Impact of Contralateral Carotid Occlusion in Patients Undergoing Carotid Artery Revascularization.

Journal Article J Am Coll Cardiol · February 23, 2021 BACKGROUND: The presence of a contralateral carotid occlusion (CCO) is an established high-risk feature for patients undergoing carotid endarterectomy (CEA) and is traditionally an indication for carotid artery stenting (CAS). Recent observational data hav ... Full text Link to item Cite

Survival and Causes of Death Among Veterans With Lower Extremity Revascularization With Paclitaxel-Coated Devices: Insights From the Veterans Health Administration.

Journal Article J Am Heart Assoc · February 16, 2021 BACKGROUND The long-term safety of paclitaxel-coated devices (PCDs; drug-coated balloon or drug-eluting stent) for peripheral endovascular intervention is uncertain. We used data from the Veterans Health Administration to evaluate the association between P ... Full text Link to item Cite

2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Journal Article Circulation · February 2, 2021 AIM: This executive summary of the valvular heart disease guideline provides recommendations for clinicians to diagnose and manage valvular heart disease as well as supporting documentation to encourage their use. METHODS: A comprehensive literature search ... Full text Link to item Cite

Characteristics and Outcomes of Patients With Diabetes Mellitus Undergoing Peripheral Vascular Intervention for Infrainguinal Symptomatic Peripheral Artery Disease.

Journal Article Vasc Endovascular Surg · February 2021 PURPOSE: Patients with diabetes mellitus (DM) are known to be at higher risk for peripheral artery disease (PAD), amputations, and major adverse cardiovascular events, though it is unclear whether they are at any higher risk for repeat intervention. LIBERT ... Full text Link to item Cite

Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis.

Journal Article Am Heart J · February 2021 UNLABELLED: Morbidity and mortality associated with COVID-19 has increased exponentially, and patients with cardiovascular (CV) disease are at risk for poor outcomes. Several lines of evidence suggest a potential role for CV therapies in COVID-19 treatment ... Full text Link to item Cite

Streamlining the institutional review board process in pragmatic randomized clinical trials: challenges and lessons learned from the Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) trial.

Journal Article Trials · January 25, 2021 BACKGROUND: New considerations during the ethical review processes may emerge from innovative, yet unfamiliar operational methods enabled in pragmatic randomized controlled trials (RCT), potentially making institutional review board (IRB) evaluation more c ... Full text Link to item Cite

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.

Journal Article N Engl J Med · January 14, 2021 BACKGROUND: The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS: We randomly assigne ... Full text Link to item Cite

Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial.

Journal Article Int J Chron Obstruct Pulmon Dis · 2021 BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) are at increased risk of developing lower extremity peripheral artery disease (PAD) and suffering PAD-related morbidity and mortality. However, the effect and burden of COPD on patients ... Full text Link to item Cite

Risk Factor Burden and Long-Term Prognosis of Patients With Premature Coronary Artery Disease.

Journal Article J Am Heart Assoc · December 15, 2020 Background Coronary artery disease (CAD) is increasing among young adults. We aimed to describe the cardiovascular risk factors and long-term prognosis of premature CAD. Methods and Results Using the Duke Databank for Cardiovascular Disease, we evaluated 3 ... Full text Link to item Cite

Treatment selection and medication adherence for stable angina: The role of area-based health literacy.

Journal Article J Eval Clin Pract · December 2020 RATIONALE, AIMS, AND OBJECTIVES: Clinical studies show equivalent health outcomes from interventional procedures and treatment with medication only for stable angina patients. However, patients may be subject to overuse or access barriers for interventiona ... Full text Link to item Cite

Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy.

Journal Article Atherosclerosis · December 2020 BACKGROUND AND AIMS: Polyvascular disease (PVD) affects approximately 20% of patients with atherosclerosis and is a strong independent risk factor for ischemic outcomes. However, guidelines do not address screening or treatment for PVD, and there have been ... Full text Link to item Cite

Use of hospital resources in the care of patients with intermediate risk pulmonary embolism.

Journal Article Eur Heart J Acute Cardiovasc Care · November 27, 2020 BACKGROUND: Risk stratification and management of hemodynamically stable pulmonary embolism remains challenging. Professional societies have published stratification schemes, but little is known about the management of patients with intermediate risk pulmo ... Full text Link to item Cite

Exercise for people living with frailty and receiving haemodialysis: a mixed-methods randomised controlled feasibility study.

Journal Article BMJ Open · November 3, 2020 OBJECTIVES: Frailty is highly prevalent in haemodialysis (HD) patients, leading to poor outcomes. This study aimed to determine whether a randomised controlled trial (RCT) of intradialytic exercise is feasible for frail HD patients, and explore how the int ... Full text Link to item Cite

The impact of chronic kidney disease on outcomes following peripheral vascular intervention.

Journal Article Clin Cardiol · November 2020 BACKGROUND: Patients with chronic kidney disease (CKD) have worsened clinical outcomes following percutaneous coronary intervention; however, limited evidence exists in patients undergoing peripheral vascular intervention (PVI). PURPOSE: We aimed to assess ... Full text Link to item Cite

Cause of Death Among Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.

Journal Article Circ Cardiovasc Qual Outcomes · November 2020 BACKGROUND: Peripheral artery disease is common and associated with high mortality. There are limited data detailing causes of death among patients with peripheral artery disease. METHODS: EUCLID (Examining Use of Ticagrelor in Peripheral Artery Disease) w ... Full text Link to item Cite

Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease) Trial.

Journal Article J Am Heart Assoc · October 20, 2020 Background There are limited data on health status instruments in patients with peripheral artery disease and cardiovascular and limb events. We evaluated the relationship between health status changes and cardiovascular and limb events. Methods and Result ... Full text Link to item Cite

Corrigendum to "Effectiveness and Safety of Oral Anticoagulants in Adults with Non-valvular Atrial Fibrillation Patients and Concomitant Coronary/Peripheral Artery Disease" American Journal of Medicine 131:09 (2018): 1074-1085.e4.

Journal Article Am J Med · October 2020 There were 33,269 apixaban-warfarin, 9,345 dabigatran-warfarin, and 42,156 rivaroxaban-warfarin matched pairs, with a median follow-up of 4-5 months. Compared with warfarin, apixaban was associated with lower rates of stroke/systemic embolism (hazard ratio ... Full text Link to item Cite

Skeletal muscle capillary density is related to anaerobic threshold and claudication in peripheral artery disease.

Journal Article Vasc Med · October 2020 Peripheral artery disease (PAD) is characterized by impaired blood flow to the lower extremities, causing claudication and exercise intolerance. Exercise intolerance may result from reduced skeletal muscle capillary density and impaired muscle oxygen deliv ... Full text Link to item Cite

Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.

Journal Article Circ Cardiovasc Interv · October 2020 BACKGROUND: Patients with peripheral artery disease have a high risk of future cardiovascular disease events and mortality. Little is known about the changes in symptom classification over time in patients with peripheral artery disease and the association ... Full text Link to item Cite

Use of Natural Language Processing to Improve Identification of Patients With Peripheral Artery Disease.

Journal Article Circ Cardiovasc Interv · October 2020 BACKGROUND: Peripheral artery disease (PAD) is underrecognized, undertreated, and understudied: each of these endeavors requires efficient and accurate identification of patients with PAD. Currently, PAD patient identification relies on diagnosis/procedure ... Full text Link to item Cite

Splanchnic Nerve Block for Chronic Heart Failure.

Journal Article JACC Heart Fail · September 2020 OBJECTIVES: We hypothesized that splanchnic nerve blockade (SNB) would attenuate increased exercise-induced cardiac filling pressures in patients with chronic HF. BACKGROUND: Chronic heart failure (HF) is characterized by limited exercise capacity driven i ... Full text Link to item Cite

Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID Trial.

Journal Article Circ Cardiovasc Qual Outcomes · September 2020 BACKGROUND: Current guidelines recommend aggressive management of hypertension. Recent evidence suggested potential harm with low blood pressure targets in patients with peripheral artery disease. We investigated the association of a history of hypertensio ... Full text Link to item Cite

Model-Based Algorithms for Detecting Peripheral Artery Disease Using Administrative Data From an Electronic Health Record Data System: Algorithm Development Study.

Journal Article JMIR Med Inform · August 19, 2020 BACKGROUND: Peripheral artery disease (PAD) affects 8 to 10 million Americans, who face significantly elevated risks of both mortality and major limb events such as amputation. Unfortunately, PAD is relatively underdiagnosed, undertreated, and underresearc ... Full text Link to item Cite

Socio-demographic heterogeneity in the prevalence of COVID-19 during lockdown is associated with ethnicity and household size: Results from an observational cohort study

Journal Article Eclinicalmedicine · August 1, 2020 Background: Accumulating evidence indicates that COVID-19 causes adverse outcomes in ethnic minority groups. However, little is known about the impact of ethnicity and household size on acquiring infection with SARS-CoV-2. Methods: We undertook a retrospec ... Full text Cite

A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response.

Journal Article Am Heart J · July 2020 The infection caused by severe acute respiratory syndrome coronavirus-2, or COVID-19, can result in myocardial injury, heart failure, and arrhythmias. In addition to the viral infection itself, investigational therapies for the infection can interact with ... Full text Link to item Cite

Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.

Journal Article Circ Cardiovasc Qual Outcomes · July 2020 BACKGROUND: Peripheral artery disease (PAD) is associated with increased risk of mortality, cardiovascular morbidity, and major amputation. Data on major amputation from a large randomized trial that included a substantial cohort of patients without critic ... Full text Link to item Cite

Understanding the patient experience of pain and discomfort during cardiac catheterization.

Journal Article Catheter Cardiovasc Interv · June 1, 2020 OBJECTIVES: Patient centeredness is an essential component of high-quality care, yet little is known regarding the patient experience during procedures performed in the cardiac catheterization lab. BACKGROUND: Available literature focuses on the safe deliv ... Full text Link to item Cite

Computable Phenotype Implementation for a National, Multicenter Pragmatic Clinical Trial: Lessons Learned From ADAPTABLE.

Journal Article Circ Cardiovasc Qual Outcomes · June 2020 BACKGROUND: Many large-scale cardiovascular clinical trials are plagued with escalating costs and low enrollment. Implementing a computable phenotype, which is a set of executable algorithms, to identify a group of clinical characteristics derivable from e ... Full text Link to item Cite

Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial.

Journal Article Lancet · May 2, 2020 BACKGROUND: Catheter-based renal denervation has significantly reduced blood pressure in previous studies. Following a positive pilot trial, the SPYRAL HTN-OFF MED (SPYRAL Pivotal) trial was designed to assess the efficacy of renal denervation in the absen ... Full text Link to item Cite

Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial.

Journal Article JAMA Cardiol · May 1, 2020 IMPORTANCE: Determining the right dosage of aspirin for the secondary prevention treatment of atherosclerotic cardiovascular disease (ASCVD) remains an unanswered and critical question. OBJECTIVE: To report the rationale and design for a randomized clinica ... Full text Link to item Cite

Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated events.

Journal Article Trials · April 9, 2020 BACKGROUND: The primary goal of phase 2 and 3 clinical trials is to evaluate the safety and effectiveness of therapeutic interventions, and efficient and reproducible ascertainment of important clinical events, either as clinical outcome events (COEs) or a ... Full text Link to item Cite

Technical consideration in acute myocardial infarction with cardiogenic shock: A review of antithrombotic and PCI therapies.

Journal Article Catheter Cardiovasc Interv · April 1, 2020 In this review, we report a contemporary appraisal of the available evidence focusing on adjunctive antithrombotic therapy and technical aspects of percutaneous coronary interventions (PCI) in patients with acute myocardial infarction and cardiogenic shock ... Full text Link to item Cite

Role of health plan administrative claims data in participant recruitment for pragmatic clinical trials: An Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) example.

Journal Article Clin Trials · April 2020 AIM: The purpose of this study is to evaluate HealthCore/Anthem Research Network recruitment strategies, compare response and enrollment rates for different recruitment strategies, and describe demographic and clinical characteristics of responders and enr ... Full text Link to item Cite

RISK PROFILE AND LONG-TERM PROGNOSIS OF PATIENTS WITH PREMATURE CORONARY ARTERY DISEASE

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · March 24, 2020 Link to item Cite

LAWN MOWER VS. LEFT VENTRICULAR ASSIST DEVICE: A CASE OF TRAUMATIC CORONARY INJURY

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · March 24, 2020 Link to item Cite

Lawn Mower Versus Left Ventricular Assist Device: A Case of Traumatic Coronary Injury.

Journal Article JACC Case Rep · March 2020 A 77-year-old man with history of ischemic cardiomyopathy and left ventricular assist device (LVAD) presented with abdominal pain after a lawn mower accident. Examination and imaging revealed a displaced LVAD driveline and a pericardial hematoma secondary ... Full text Open Access Link to item Cite

Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease.

Journal Article J Am Coll Cardiol · February 18, 2020 BACKGROUND: Patients with peripheral artery disease (PAD) have a higher risk of major adverse cardiovascular events (MACE) compared with those without PAD. OBJECTIVES: The aim of this post hoc analysis was to evaluate sex-specific differences in MACE and l ... Full text Link to item Cite

Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial.

Journal Article Am Heart J · February 2020 BACKGROUND: Rates and predictors of major bleeding in patients with peripheral artery disease (PAD) treated with antiplatelets have not been well studied. This post hoc analysis of EUCLID aimed to determine the incidence of major/minor bleeding, predictors ... Full text Open Access Link to item Cite

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.

Journal Article J Am Coll Cardiol · January 21, 2020 BACKGROUND: Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C). OBJECTIVES: A pre-specified ana ... Full text Link to item Cite

Changes in the optimal cardiac resynchronization therapy pacing configuration during physiologic stress.

Journal Article J Electrocardiol · 2020 BACKGROUND: Some patients with ongoing heart failure symptoms after treatment with cardiac resynchronization therapy (CRT) demonstrate QRS prolongation during exercise. We investigated whether the optimal CRT pacing configuration changes during dobutamine ... Full text Link to item Cite

Challenges of one-year longitudinal follow-up of a prospective, observational cohort study using an anonymised database: Recommendations for trainee research collaboratives

Journal Article BMC Medical Research Methodology · December 12, 2019 Background: Trainee research collaboratives (TRCs) have pioneered high quality, prospective 'snap-shot' surgical cohort studies in the UK. Outcomes After Kidney injury in Surgery (OAKS) was the first TRC cohort study to attempt to collect one-year follow-u ... Full text Cite

Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.

Journal Article Circulation · December 3, 2019 BACKGROUND: The safety and efficacy of antithrombotic regimens may differ between patients with atrial fibrillation who have acute coronary syndromes (ACS), treated medically or with percutaneous coronary intervention (PCI), and those undergoing elective P ... Full text Link to item Cite

Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.

Journal Article Circ Cardiovasc Interv · December 2019 BACKGROUND: Recent trials have identified anti-diabetes mellitus agents that lower major adverse cardiovascular event (MACE) rates, although some increase rates of lower-extremity amputation (LEA). Patients with peripheral artery disease (PAD) have greater ... Full text Link to item Cite

Polyvascular Disease: Reappraisal of the Current Clinical Landscape.

Journal Article Circ Cardiovasc Interv · December 2019 Atherosclerosis within 2 or more arterial beds has been termed polyvascular disease. Although polyvascular disease has long been associated with heightened cardiovascular risk, much is still unknown regarding its pathophysiology and management. In this pas ... Full text Link to item Cite

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.

Journal Article Circulation · November 5, 2019 BACKGROUND: The 2018 US cholesterol management guidelines recommend additional lipid-lowering therapies for secondary prevention in patients with low-density lipoprotein cholesterol ≥70 mg/dL or non-high-density lipoprotein cholesterol ≥100 mg/dL despite m ... Full text Link to item Cite

Use and 1-year outcomes with conventional and drug-coated balloon angioplasty in patients with lower extremity peripheral artery disease.

Journal Article Am Heart J · November 2019 BACKGROUND: With the growing use of drug-coated balloons for the treatment of peripheral artery disease, information regarding the safety and effectiveness of drug-coated balloons in current practice is needed. We examined patient, physician, and procedura ... Full text Link to item Cite

Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial.

Journal Article Circ Cardiovasc Qual Outcomes · November 2019 BACKGROUND: In ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), alirocumab was compared with placebo, added to high-intensity or maximum tolerated statin treatment after acute coron ... Full text Link to item Cite

Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial.

Journal Article Vasc Med · October 2019 In patients with symptomatic peripheral artery disease (PAD), the impact of chronic kidney disease (CKD) on major adverse cardiovascular events has not been fully evaluated. The Examining Use of Ticagrelor In PAD (EUCLID) trial randomized 13,885 patients w ... Full text Open Access Link to item Cite

Expanding opportunities to understand quality and outcomes of peripheral vascular interventions: The ACC NCDR PVI Registry.

Journal Article Am Heart J · October 2019 Lower extremity peripheral artery disease (PAD) and cerebrovascular disease (CeVD) are prevalent conditions in the United States, and both are associated with significant morbidity (eg, stroke, myocardial infarction, and limb loss) and increased mortality. ... Full text Link to item Cite

Identification, diagnosis, treatment, and in-hospital outcomes of acute pulmonary embolism: Results from a single integrated health system.

Journal Article Am Heart J · October 2019 BACKGROUND: Although the high-risk acute pulmonary embolism (PE) population has been described, little is known about the contemporary inpatient experience and practice patterns of the PE population as a whole. METHODS: All patients with a diagnosis of acu ... Full text Link to item Cite

Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID Trial.

Journal Article Circ Cardiovasc Interv · October 2019 BACKGROUND: The relationship between invasive vascular procedures and bleeding in patients with peripheral artery disease has not been well described in the literature. This post hoc analysis from the EUCLID trial (Examining Use of Ticagrelor in Peripheral ... Full text Open Access Link to item Cite

Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease.

Journal Article Circulation · September 24, 2019 Aspirin is the cornerstone of the antithrombotic management of patients with established atherosclerotic cardiovascular disease, but major guidelines provide conflicting recommendations for its use in primary prevention. Findings from recent randomized tri ... Full text Link to item Cite

Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery.

Journal Article J Am Coll Cardiol · September 3, 2019 BACKGROUND: Patients with acute coronary syndrome (ACS) and history of coronary artery bypass grafting (CABG) are at high risk for recurrent cardiovascular events and death. OBJECTIVES: This study sought to determine the clinical benefit of adding alirocum ... Full text Link to item Cite

Acute Limb Ischemia in Peripheral Artery Disease.

Journal Article Circulation · August 13, 2019 BACKGROUND: Acute limb ischemia (ALI) is an important clinical event and an emerging cardiovascular clinical trial outcome. Risk factors for and outcomes after ALI have not been fully evaluated. METHODS: EUCLID (Examining Use of Ticagrelor in Peripheral Ar ... Full text Open Access Link to item Cite

Patient-Clinician Decision Making for Stable Angina: The Role of Health Literacy.

Journal Article EGEMS (Wash DC) · August 9, 2019 BACKGROUND: Stable angina patients have difficulty understanding the tradeoffs between treatment alternatives. In this analysis, we assessed treatment planning conversations for stable angina to determine whether inadequate health literacy acts as a barrie ... Full text Link to item Cite

Administrative claims data to support pragmatic clinical trial outcome ascertainment on cardiovascular health.

Journal Article Clin Trials · August 2019 BACKGROUND/AIMS: Health plan administrative claims data present a cost-effective complement to traditional trial-specific ascertainment of clinical events typically conducted through patient report or a single health system electronic health record. We aim ... Full text Link to item Cite

Atrial Fibrillation and Percutaneous Coronary Intervention.

Journal Article Circ Cardiovasc Interv · August 2019 Full text Link to item Cite

Correction

Journal Article Journal of the American College of Cardiology · July 2019 Full text Cite

Bleeding Complications in Lower-Extremity Peripheral Vascular Interventions: Insights From the NCDR PVI Registry.

Journal Article JACC Cardiovasc Interv · June 24, 2019 OBJECTIVES: This study sought to assess periprocedural bleeding complications in lower-extremity peripheral vascular interventions (PVIs). BACKGROUND: Few studies have examined the incidence, predictors, or outcomes of periprocedural bleeding after lower-e ... Full text Link to item Cite

Stroke in Patients With Peripheral Artery Disease.

Journal Article Stroke · June 2019 Background and Purpose- Predictors of stroke and transient ischemic attack (TIA) in patients with peripheral artery disease (PAD) are poorly understood. The primary aims of this analysis were to (1) determine the incidence of ischemic/hemorrhagic stroke an ... Full text Open Access Link to item Cite

Size of Anterior Wall Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention in United States Versus Europe/Australia Versus India (from the CRISP-AMI Randomized Controlled Trial).

Journal Article Am J Cardiol · April 1, 2019 International variability in infarct size following acute anterior ST-elevation myocardial infarction without shock treated with primary percutaneous coronary intervention (PCI) has been little studied. Patients enrolled in the Counterpulsation to Reduce I ... Full text Link to item Cite

Patient Radiation Dosage During Lower Extremity Endovascular Intervention.

Journal Article JACC Cardiovasc Interv · March 11, 2019 OBJECTIVES: The aims of this study were to determine the incidence of actionably high radiation dosages and to identify predictors of increased patient dosage. BACKGROUND: Peripheral endovascular intervention using fluoroscopic imaging has become a mainsta ... Full text Link to item Cite

Ankle-brachial index in patients with intermittent claudication is a poor indicator of patient-centered and clinician-based evaluations of functional status.

Journal Article J Vasc Surg · March 2019 BACKGROUND: The association between the severity of ankle-brachial index (ABI), a traditional measure of the severity of peripheral artery disease (PAD), and patients' perceptions of their health status is poorly characterized. In Patient-Centered Outcomes ... Full text Link to item Cite

First-in-human experience with Aortix intraaortic pump.

Conference Catheter Cardiovasc Interv · February 15, 2019 BACKGROUND: There are limited options for percutaneous mechanical circulatory support (pMCS) in patients requiring high-risk percutaneous coronary intervention. OBJECTIVES: This first-in-human, single-center study aimed to evaluate the safety and feasibili ... Full text Link to item Cite

Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials.

Journal Article Circulation · February 12, 2019 BACKGROUND: Modern cardiometabolic clinical trials often include cardiovascular death as a component of a composite primary outcome, requiring central adjudication by a clinical events committee to classify cause of death. However, sometimes the cause of d ... Full text Link to item Cite

Predictive Model for High-Risk Coronary Artery Disease.

Journal Article Circ Cardiovasc Imaging · February 2019 BACKGROUND: Patients with high-risk coronary artery disease (CAD) may be difficult to identify. METHODS: Using the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) cohort randomized to coronary computed tomographic angiography ( ... Full text Link to item Cite

PREPARED Study: A Study of Shared Decision-Making for Coronary Artery Disease.

Journal Article Circ Cardiovasc Qual Outcomes · February 2019 Background Guidelines recommend patient engagement in shared decision-making regarding coronary revascularization, but studies demonstrate poor patient understanding of risks, benefits, and alternatives. Effective strategies are needed to integrate informe ... Full text Link to item Cite

Endovascular treatment of femoro-popliteal lesions.

Journal Article Clin Cardiol · January 2019 Peripheral artery disease (PAD) is a major health concern affecting more than 200 million people worldwide and studies have shown PAD to be a strong predictor of mortality, morbidity, and disability. The management of PAD is multi-tiered and advancements i ... Full text Link to item Cite

Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.

Journal Article JAMA Cardiol · January 1, 2019 IMPORTANCE: Patients with peripheral artery disease (PAD) are at high risk for myocardial infarction (MI). OBJECTIVE: To characterize the incidence and types of MI in a PAD population, identify factors associated with MI, and determine the association of M ... Full text Open Access Link to item Cite

Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial.

Journal Article J Am Coll Cardiol · December 25, 2018 BACKGROUND: Diabetes confers an increased risk for atherosclerotic cardiovascular disease, but less is known about the independent risk diabetes confers on major cardiovascular and limb events in patients with symptomatic peripheral artery disease (PAD) on ... Full text Open Access Link to item Cite

Ticagrelor in Peripheral Artery Disease Endovascular Revascularization (TI-PAD): Challenges in clinical trial execution.

Journal Article Vasc Med · December 2018 There is limited evidence to guide clinical decision-making for antiplatelet therapy in peripheral artery disease (PAD) in the setting of lower extremity endovascular treatment. The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Stu ... Full text Link to item Cite

Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.

Journal Article Vasc Med · December 2018 Patients with peripheral artery disease (PAD) are at heightened risk of cardiovascular morbidity and mortality. We sought to evaluate the risk of concomitant coronary artery disease (CAD) in patients with symptomatic PAD versus PAD without diagnosed CAD, a ... Full text Open Access Link to item Cite

Validation of a claims-based algorithm identifying eligible study subjects in the ADAPTABLE pragmatic clinical trial.

Journal Article Contemp Clin Trials Commun · December 2018 OBJECTIVE: Validate an algorithm that uses administrative claims data to identify eligible study subjects for the ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) pragmatic clinical trial (PCT). MATERIALS A ... Full text Link to item Cite

Femoropopliteal In-Stent Restenosis.

Journal Article Circ Cardiovasc Interv · December 2018 Full text Link to item Cite

Predictors and Outcomes of Staged Versus One-Time Multivessel Revascularization in Multivessel Coronary Artery Disease: Insights From the VA CART Program.

Journal Article JACC Cardiovasc Interv · November 26, 2018 OBJECTIVES: The aim of this study was to determine predictors and outcomes associated with staged percutaneous coronary intervention (PCI) versus one-time multivessel revascularization (OTMVR) in patients with multivessel coronary artery disease. BACKGROUN ... Full text Link to item Cite

Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial.

Journal Article JAMA Netw Open · November 2, 2018 IMPORTANCE: The effect of polyvascular disease on cardiovascular outcomes in the background of peripheral artery disease (PAD) is unclear. OBJECTIVE: To determine the risk of ischemic events (both cardiac and limb) among patients with PAD and polyvascular ... Full text Open Access Link to item Cite

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Journal Article Lancet · October 27, 2018 BACKGROUND: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine t ... Full text Link to item Cite

New Curveball for Hypertension Guidelines?

Journal Article Circulation · October 23, 2018 Full text Link to item Cite

Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization: The EUCLID Trial.

Journal Article J Am Coll Cardiol · October 2, 2018 BACKGROUND: Lower extremity revascularization (LER) is a common treatment in patients with peripheral artery disease (PAD), but long-term outcomes are poorly defined. OBJECTIVES: The aim was to analyze LER in the EUCLID (Examining Use of tiCagreLor In paD) ... Full text Open Access Link to item Cite

Exploring Meaningful Patient Engagement in ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness).

Journal Article Med Care · October 2018 BACKGROUND: Genuine patient engagement can improve research relevance, impact and is required for studies using the National Patient-Centered Clinical Research Network including major multicenter research projects. It is unclear, however, how best to integ ... Full text Link to item Cite

Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.

Journal Article Am J Med · September 2018 BACKGROUND: Direct oral anticoagulants (DOAC) are at least non-inferior to warfarin in efficacy and safety among patients with nonvalvular atrial fibrillation. Limited evidence is available regarding outcomes for nonvalvular atrial fibrillation patients wi ... Full text Link to item Cite

Effects of a 12-Week mHealth Program on FunctionalCapacity and Physical Activity in Patients With PeripheralArtery Disease.

Journal Article Am J Cardiol · September 1, 2018 Supervised exercise is beneficial for peripheral artery disease (PAD) patients limited by intermittent claudication (IC). However, supervised exercise for PAD remains widely underutilized. Mobile health (mHealth) provides an intermediate solution between s ... Full text Link to item Cite

Splanchnic Nerve Block for Acute Heart Failure.

Journal Article Circulation · August 28, 2018 Full text Link to item Cite

Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome.

Journal Article American heart journal · July 2018 BackgroundPatients with peripheral artery disease (PAD) are known to have an increased risk of ischemic cardiovascular events. However, the influence of concomitant PAD on first and subsequent recurrent ischemic events after an acute coronary synd ... Full text Cite

Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing Transcatheter Aortic Valve Replacement.

Journal Article Circ Cardiovasc Interv · June 2018 BACKGROUND: Stroke is a serious complication of both transcatheter aortic valve replacement (TAVR) and carotid artery disease (CD). The implications of CD in patients undergoing TAVR are unclear. METHODS AND RESULTS: The Society of Thoracic Surgeons and Am ... Full text Link to item Cite

Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial.

Journal Article Lancet · May 19, 2018 BACKGROUND: Few studies have examined the efficacy of drug-eluting stents (DES) for reducing aortocoronary saphenous vein bypass graft (SVG) failure compared with bare-metal stents (BMS) in patients undergoing stenting of de-novo SVG lesions. We assessed t ... Full text Link to item Cite

Public Health Impact of the Centers for Medicare and Medicaid Services Decision on Pass-Through Add-On Payments for Drug-Coated Balloons: A Call to Action.

Journal Article JACC Cardiovasc Interv · March 12, 2018 On Wednesday, November 1, 2017, the Centers for Medicare and Medicaid Services (CMS) made a public decision to end the transitional pass-through add-on payment for drug-coated balloons beginning January 1, 2018, without creating a new ambulatory payment cl ... Full text Link to item Cite

Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.

Journal Article Am Heart J · March 2018 BACKGROUND: We assessed antiplatelet therapy use and outcomes in patients undergoing percutaneous coronary intervention (PCI) during the ARISTOTLE trial. METHODS: Patients were categorized based on the occurrence of PCI during follow-up (median 1.8 years); ... Full text Link to item Cite

ELECTRONIC HEALTH RECORD ALGORITHMS TO DETECT PAD

Conference Journal of the American College of Cardiology · March 2018 Full text Cite

MAJOR BLEEDING IN PATIENTS WITH PERIPHERAL ARTERY DISEASE: INSIGHTS FROM THE EUCLID TRIAL

Conference Journal of the American College of Cardiology · March 2018 Full text Cite

Systematic review and meta-analysis of endovascular and surgical revascularization for patients with chronic lower extremity venous insufficiency and varicose veins.

Journal Article Am Heart J · February 2018 BACKGROUND: Chronic lower extremity venous disease (LECVD) is twice as prevalent as coronary heart disease, and invasive therapies to treat LECVD accounted for an estimated $290 million in Medicare expenditures in 2015. Despite increasing use of these inva ... Full text Link to item Cite

Registry Assessment of Peripheral Interventional Devices (RAPID): Registry assessment of peripheral interventional devices core data elements.

Journal Article J Vasc Surg · February 2018 OBJECTIVE: The current state of evaluating patients with peripheral artery disease and more specifically of evaluating medical devices used for peripheral vascular intervention (PVI) remains challenging because of the heterogeneity of the disease process, ... Full text Link to item Cite

Lower Repeat Revascularization Rates Among Patients With Prior Coronary Artery Bypass Graft Surgery are Due to Lack of Adequate Target Vessels.

Journal Article J Invasive Cardiol · February 2018 BACKGROUND: Studies comparing percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) surgery in patients with multivessel coronary artery disease (CAD) have shown lower repeat revascularization rates in patients who undergo CABG. ... Link to item Cite

PORTRAIT (Patient-Centered Outcomes Related to Treatment Practices in Peripheral Arterial Disease: Investigating Trajectories): Overview of Design and Rationale of an International Prospective Peripheral Arterial Disease Study.

Journal Article Circ Cardiovasc Qual Outcomes · February 2018 BACKGROUND: Health status outcomes, including symptoms, functional status, and quality of life, are critically important outcomes from patients' perspectives. The PORTRAIT study (Patient-Centered Outcomes Related to Treatment Practices in Peripheral Arteri ... Full text Link to item Cite

Registry Assessment of Peripheral Interventional Devices (RAPID)　- Registry Assessment of Peripheral Interventional Devices Core Data Elements.

Journal Article Circ J · January 25, 2018 BACKGROUND: The current state of evaluating patients with peripheral artery disease and more specifically of evaluating medical devices used for peripheral vascular intervention (PVI) remains challenging because of the heterogeneity of the disease process, ... Full text Link to item Cite

Antithrombotic Therapy in Peripheral Artery Disease: Generating and Translating Evidence Into Practice.

Journal Article J Am Coll Cardiol · January 23, 2018 Atherosclerotic cardiovascular (CV) disease remains a major health concern affecting more than 200 million adults worldwide, and lower extremity peripheral artery disease (PAD) is associated with significant morbidity and mortality. Treatment strategies to ... Full text Link to item Cite

Antithrombotic Therapy in Peripheral Artery Disease Generating and Translating Evidence Into Practice

Journal Article JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · January 23, 2018 Link to item Cite

Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial.

Journal Article Eur J Vasc Endovasc Surg · January 2018 OBJECTIVES: Critical limb ischaemia (CLI) implies an increased risk of cardiovascular morbidity and mortality, and the optimal antithrombotic treatment is not established. DESIGN, MATERIALS, METHODS: The EUCLID trial investigated the effect of monotherapy ... Full text Open Access Link to item Cite

Antithrombotic therapy in peripheral artery disease: A review of the EUCLID trial results and current ongoing trials.

Journal Article Clin Cardiol · January 2018 In addition to risk-factor modification, antithrombotic therapy is the hallmark of management to reduce cardiovascular ischemic events in patients with peripheral artery disease (PAD). Currently, the guidelines recommend long-term antiplatelet therapy with ... Full text Link to item Cite

Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial.

Journal Article Clin Cardiol · January 2018 BACKGROUND: Atrial fibrillation (AF) increases risk of stroke 5-fold. Carotid artery disease (CD) also augments the risk of stroke, yet there are limited data about the interplay of these 2 diseases and clinical outcomes in patients with comorbid AF and CD ... Full text Link to item Cite

Understanding operator stent choice in the catheterization laboratory using a pre-procedure survey: Opportunities for quality improvement.

Journal Article Cardiovasc Revasc Med · December 2017 OBJECTIVES: We sought to characterize how the perceived risk of early dual antiplatelet therapy (DAPT) discontinuation is incorporated into operator decision-making regarding stent choice, using a simple pre-procedure survey screening for clinical variable ... Full text Open Access Link to item Cite

Triple Therapy for Atrial Fibrillation after PCI.

Journal Article N Engl J Med · October 19, 2017 Full text Link to item Cite

Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes: A Report From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Therapy Registry.

Journal Article Circ Cardiovasc Interv · October 2017 BACKGROUND: Peripheral artery disease (PAD) is associated with increased cardiovascular mortality, and PAD risk factors overlap with those for aortic stenosis. The prevalence and outcomes associated with PAD in a population undergoing transcatheter aortic ... Full text Link to item Cite

The Effect of Clinical Care Location on Clinical Outcomes After Peripheral Vascular Intervention in Medicare Beneficiaries.

Journal Article JACC Cardiovasc Interv · June 12, 2017 OBJECTIVES: Modifications in reimbursement rates by Medicare in 2008 have led to peripheral vascular interventions (PVI) being performed more commonly in outpatient and office-based clinics. The objective of this study was to determine the effects of this ... Full text Link to item Cite

National patterns in intensity and frequency of outpatient care for apparent treatment-resistant hypertension.

Journal Article Am Heart J · April 2017 BACKGROUND: Apparent treatment-resistant hypertension (aTRH) is associated with an increased risk of adverse cardiovascular outcomes. We studied the frequency and intensity of care for aTRH among participants aged 65 years and older in the US-based REGARDS ... Full text Link to item Cite

Comparison of visual assessment of coronary stenosis with independent quantitative coronary angiography: Findings from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial.

Journal Article Am Heart J · February 2017 BACKGROUND: The outcomes in patients by visual assessment and quantitative coronary angiography (QCA) for obstructive coronary artery disease (CAD) are not known. Our objectives were to compare visual and QCA estimates of obstructive CAD and to assess thei ... Full text Link to item Cite

Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease.

Journal Article Circulation · January 17, 2017 BACKGROUND: In patients with symptomatic peripheral artery disease with a history of limb revascularization, the optimal antithrombotic regimen for long-term management is unknown. METHODS: The EUCLID trial (Examining Use of Ticagrelor In PAD) randomized 1 ... Full text Link to item Cite

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.

Journal Article J Am Heart Assoc · January 17, 2017 BACKGROUND: We studied (1) the rates of stroke or systemic embolism and bleeding in patients with atrial fibrillation and peripheral artery disease (PAD) and (2) the efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation with ... Full text Link to item Cite

Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.

Journal Article N Engl J Med · January 5, 2017 BACKGROUND: Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events. Data from previous trials have suggested that patients receiving clopidogrel monotherapy had a low ... Full text Link to item Cite

Peripheral Artery Disease and Cardiovascular Risk in Patients Presenting With Chest Pain: Insights From the PROMISE Trial

Conference · 2017 Introduction: Peripheral artery disease (PAD) is considered a coronary risk equivalent and is associated with increased risk of adverse cardiovascular (CV) events. Yet, as compared to other high-risk groups, little is known about the relative risk of adver ... Cite

Impact of Non-Infarct-Related Artery Disease on Infarct Size and Outcomes (from the CRISP-AMI Trial).

Journal Article Am J Med · December 2016 BACKGROUND: Non-infarct-related artery (non-IRA) disease is prevalent in patients with ST-segment elevation myocardial infarction (STEMI). We aimed to assess the impact of non-IRA disease on infarct size and clinical outcomes in patients with acute STEMI. ... Full text Link to item Cite

The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease.

Journal Article J Am Coll Cardiol · October 25, 2016 Large randomized clinical trials in cardiovascular disease have proliferated over the past 3 decades, with results that have influenced every aspect of cardiology practice. Despite these advances, there remains a substantial need for more high-quality evid ... Full text Link to item Cite

Significant variation in P2Y12 inhibitor use after peripheral vascular intervention in Medicare beneficiaries.

Journal Article Am Heart J · September 2016 UNLABELLED: There is no consensus regarding whether to use antithrombotic medications in patients with peripheral artery disease after lower-extremity peripheral vascular intervention. OBJECTIVES: The main hypothesis is that significant variation exists re ... Full text Link to item Cite

Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.

Journal Article JACC Cardiovasc Interv · August 22, 2016 OBJECTIVES: The authors assessed the use of dual antiplatelet therapy (DAPT) and outcomes in patients undergoing percutaneous coronary intervention (PCI) during the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K ... Full text Link to item Cite

Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial.

Journal Article Am Heart J · August 2016 BACKGROUND: We conducted a retrospective analysis examining the association between systolic blood pressure (SBP) or hypertension bracket and stroke risk in patients with atrial fibrillation (AF). METHODS: The study included 14,256 anticoagulated patients ... Full text Link to item Cite

The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease.

Journal Article Curr Cardiol Rep · August 2016 Coronary artery disease (CAD) is the underlying cause of death in one out of seven deaths in the USA. Aspirin therapy has been proven to decrease mortality and major adverse cardiovascular events in patients with CAD. Despite a plethora of studies showing ... Full text Link to item Cite

Endpoint Assessment for Cell Therapy in Patients with Intermittent Claudication and Critical Limb Ischemia

Chapter · June 13, 2016 Peripheral artery disease (PAD) affects over eight million Americans and is associated with significant morbidity and mortality as it is a marker of subclinical heart disease and systemic atherosclerosis (Rooke TW et al. J Am Coll Cardiol 2011;58:2020-2045 ... Full text Cite

Low-density lipoprotein cholesterol level and statin use among Medicare beneficiaries with diabetes mellitus.

Journal Article Diab Vasc Dis Res · May 2016 At the time of this study, guidelines recommended a primary goal of low-density lipoprotein cholesterol level less than 100 mg/dL for all patients, an optional goal of low-density lipoprotein cholesterol less than 70 mg/dL for patients with overt cardiovas ... Full text Link to item Cite

Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial.

Journal Article Am Heart J · May 2016 BACKGROUND: Despite overwhelming data demonstrating the efficacy of antiplatelet therapy in heart disease and stroke, data in peripheral artery disease (PAD) are less compelling. Aspirin has modest evidence supporting a reduction in cardiovascular events i ... Full text Link to item Cite

Clinical characteristics and outcomes after unplanned intraaortic balloon counterpulsation in the Counterpulsation to Reduce Infarct Size Pre-PCI Acute Myocardial Infarction trial.

Journal Article Am Heart J · April 2016 BACKGROUND: Despite advances in primary percutaneous coronary intervention (pPCI) and regional systems of care, the development of cardiogenic shock is associated with poor clinical outcomes in patients with ST-segment elevation myocardial infarction (STEM ... Full text Link to item Cite

Antithrombotic Therapy After Peripheral Vascular Intervention.

Journal Article Curr Cardiol Rep · March 2016 Cardioprotective medications and risk-factor modification are the hallmarks of treatment for all patients with peripheral artery disease (PAD). If symptoms are life-limiting and/or do not respond to conservative treatment, endovascular or surgical revascul ... Full text Link to item Cite

The Contemporary Safety and Effectiveness of Lower Extremity Bypass Surgery and Peripheral Endovascular Interventions in the Treatment of Symptomatic Peripheral Arterial Disease.

Journal Article Circulation · November 24, 2015 BACKGROUND: Treatment for symptomatic peripheral artery disease includes lower extremity bypass surgery (LEB) and peripheral endovascular interventions (PVIs); however, limited comparative effectiveness data exist between the 2 therapies. We assessed the s ... Full text Link to item Cite

Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review.

Journal Article J Am Heart Assoc · October 29, 2015 BACKGROUND: Observational studies evaluating the possible interaction between proton pump inhibitors (PPIs) and clopidogrel have shown mixed results. We conducted a systematic review comparing the safety of individual PPIs in patients with coronary artery ... Full text Open Access Link to item Cite

ADAM12: a genetic modifier of preclinical peripheral arterial disease.

Journal Article Am J Physiol Heart Circ Physiol · September 2015 In prior studies from multiple groups, outcomes following experimental peripheral arterial disease (PAD) differed considerably across inbred mouse strains. Similarly, in humans with PAD, disease outcomes differ, even when there are similarities in risk fac ... Full text Link to item Cite

Management of cardiogenic shock in the setting of ST-elevation myocardial infarction: controversies and future directions.

Journal Article Minerva Cardioangiol · August 2015 The treatment of patients with ST-segment elevation myocardial infarction (STEMI) has changed dramatically since reperfusion therapy has been adopted more commonly, yet 5-10% of patients still develop cardiogenic shock and remain a therapeutic challenge in ... Link to item Cite

Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization.

Journal Article Am Heart J · August 2015 BACKGROUND: Although the presence, extent, and severity of obstruction in patients with lower extremity peripheral artery disease (LE PAD) affect their functional status, quality of life, and treatment, it is not known if these factors are associated with ... Full text Link to item Cite

Letter response.

Journal Article Am Heart J · August 2015 Full text Link to item Cite

Limb ischemia: cardiovascular diagnosis and management from head to toe.

Journal Article Curr Cardiol Rep · July 2015 Peripheral arterial disease (PAD) affects an estimated 27 million people in Europe and North America. Limb ischemia, defined as ischemic rest pain, ischemic ulcerations, or ischemic gangrene, represents the most severe manifestation of PAD and is associate ... Full text Link to item Cite

Supervised vs unsupervised exercise for intermittent claudication: A systematic review and meta-analysis.

Journal Article Am Heart J · June 2015 BACKGROUND: Supervised exercise (SE) is widely accepted as an effective therapy for intermittent claudication (IC), but its use is limited by cost. Unsupervised exercise (UE) represents a less costly alternative. We assessed the comparative effectiveness o ... Full text Link to item Cite

Comparative Effectiveness of Medical Therapy, Supervised Exercise, and Revascularization for Patients With Intermittent Claudication: A Network Meta-analysis.

Journal Article Clin Cardiol · June 2015 BACKGROUND: There are limited data on the comparative effectiveness of medical therapy, supervised exercise, and revascularization to improve walking and quality of life in patients with intermittent claudication (IC). HYPOTHESIS: Supervised exercise and r ... Full text Link to item Cite

Trends in settings for peripheral vascular intervention and the effect of changes in the outpatient prospective payment system.

Journal Article J Am Coll Cardiol · March 10, 2015 BACKGROUND: Peripheral vascular intervention (PVI) is an effective treatment option for patients with peripheral artery disease (PAD). In 2008, Medicare modified reimbursement rates to encourage more efficient outpatient use of PVI in the United States. OB ... Full text Link to item Cite

Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC).

Journal Article J Am Coll Cardiol · March 10, 2015 The lack of consistent definitions and nomenclature across clinical trials of novel devices, drugs, or biologics poses a significant barrier to accrual of knowledge in and across peripheral artery disease therapies and technologies. Recognizing this proble ... Full text Link to item Cite

Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study.

Journal Article Eur J Prev Cardiol · March 2015 AIMS: Lower extremity peripheral artery disease (PAD) has been proposed as a 'coronary heart disease (CHD) risk equivalent'. We aimed to examine whether PAD confers similar risk for mortality as incident myocardial infarction (MI) and whether risk differs ... Full text Link to item Cite

The impact of processes of care on myocardial infarct size in patients with ST-segment elevation myocardial infarction: observations from the CRISP-AMI trial.

Journal Article Clin Cardiol · January 2015 BACKGROUND: Primary percutaneous coronary intervention (PCI) is the most common method of reperfusion in patients with ST-segment elevation myocardial infarction (STEMI) in the United States. The intersection between processes of care and performance measu ... Full text Link to item Cite

Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review.

Journal Article Circ Cardiovasc Qual Outcomes · January 2015 BACKGROUND: Discordant results have been reported on the effects of concomitant use of proton pump inhibitors (PPIs) and dual antiplatelet therapy (DAPT) for cardiovascular outcomes. We conducted a systematic review comparing the effectiveness and safety o ... Full text Link to item Cite

Clinical trials in peripheral vascular disease: pipeline and trial designs: an evaluation of the ClinicalTrials.gov database.

Conference Circulation · November 11, 2014 BACKGROUND: Tremendous advances have occurred in therapies for peripheral vascular disease (PVD); until recently, however, it has not been possible to examine the entire clinical trial portfolio of studies for the treatment of PVD (both arterial and venous ... Full text Link to item Cite

Dual antiplatelet therapy with or without oral anticoagulation in the postdischarge management of acute coronary syndrome patients with an indication for long term anticoagulation: a systematic review.

Journal Article J Thromb Thrombolysis · October 2014 Currently, there is a lack of consensus among guidelines for the postdischarge treatment of patients presenting with acute coronary syndrome (ACS) who have a long-term indication for anticoagulation. We conducted a systematic review comparing the safety an ... Full text Link to item Cite

Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER).

Journal Article Am Heart J · October 2014 BACKGROUND: In the TRACER trial, vorapaxar, a protease-activated receptor-1 antagonist, plus standard care in non-ST-segment elevation acute coronary syndrome (NSTE ACS) patients did not significantly reduce the primary composite end point but reduced a ke ... Full text Link to item Cite

Association of the ankle-brachial index with history of myocardial infarction and stroke.

Journal Article Am Heart J · April 2014 BACKGROUND: Ankle-brachial index (ABI) testing is a simple, noninvasive method to diagnose peripheral artery disease (PAD) and is associated with all-cause mortality. The association of ABI levels and myocardial infarction (MI) and stroke is less certain. ... Full text Link to item Cite

Comparative effectiveness of endovascular and surgical revascularization for patients with peripheral artery disease and critical limb ischemia: systematic review of revascularization in critical limb ischemia.

Journal Article Am Heart J · April 2014 BACKGROUND: For patients with critical limb ischemia (CLI), the optimal treatment to enhance limb preservation, prevent death, and improve functional status is unknown. We performed a systematic review and meta-analysis to assess the comparative effectiven ... Full text Link to item Cite

Impact of extracardiac vascular disease on vein graft failure and outcomes after coronary artery bypass surgery.

Journal Article Ann Thorac Surg · March 2014 BACKGROUND: While extracardiac vascular disease (ECVD), defined as a history of peripheral vascular disease (PVD) or cerebrovascular disease (CBVD), is common in patients undergoing coronary artery bypass graft (CABG) surgery, there are limited data availa ... Full text Link to item Cite

Combined use of warfarin and oral P2Y12 inhibitors in patients with atrial fibrillation and acute coronary syndrome.

Journal Article Clin Cardiol · March 2014 BACKGROUND: Although atrial fibrillation (AF) occurs frequently in patients hospitalized with acute coronary syndrome (ACS), strategies for prevention of thromboembolic complications are poorly characterized. HYPOTHESIS: We sought to examine exposure to wa ... Full text Link to item Cite

Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF.

Journal Article Eur Heart J · January 2014 AIMS: Vascular disease is included in a risk scoring system to predict stroke in patients with non-valvular atrial fibrillation (AF). This post hoc analysis of ROCKET AF aimed to determine the absolute rates of stroke and bleeding, and the relative effecti ... Full text Link to item Cite

Peripheral arterial testing before lower extremity amputation among Medicare beneficiaries, 2000 to 2010.

Journal Article Circ Cardiovasc Qual Outcomes · January 2014 BACKGROUND: Despite mild reductions in rates of lower extremity amputation over the past decade, few data exist on the use of arterial testing in patients before amputation. METHODS AND RESULTS: Using Medicare claims from 2000 through 2010, we examined rat ... Full text Link to item Cite

Lower extremity amputation in peripheral artery disease: improving patient outcomes.

Journal Article Vasc Health Risk Manag · 2014 Peripheral artery disease affects over eight million Americans and is associated with an increased risk of mortality, cardiovascular disease, functional limitation, and limb loss. In its most severe form, critical limb ischemia, patients are often treated ... Full text Link to item Cite

Socioeconomic disparities in the use of cardioprotective medications among patients with peripheral artery disease: an analysis of the American College of Cardiology's NCDR PINNACLE Registry.

Conference J Am Coll Cardiol · July 2, 2013 OBJECTIVES: The aim of this paper was to examine disparities in the use of cardioprotective medications in the treatment of peripheral artery disease (PAD) by socioeconomic status (SES). BACKGROUND: PAD is associated with increased cardiovascular risk and ... Full text Link to item Cite

Interventional treatment of hypertension: a new paradigm.

Journal Article Curr Cardiol Rep · May 2013 Hypertension is thought to contribute to more than 7 million deaths worldwide each year and contributes to the development of atherosclerotic lesions that lead to myocardial infarction and stroke. While lifestyle modifications (diet, exercise, weight loss) ... Full text Link to item Cite

High mortality risks after major lower extremity amputation in Medicare patients with peripheral artery disease.

Journal Article Am Heart J · May 2013 BACKGROUND: Little is known regarding the contemporary outcomes of older patients with peripheral artery disease (PAD) undergoing major lower extremity (LE) amputation in the United States. We sought to characterize clinical outcomes and factors associated ... Full text Link to item Cite

Remote Stab Wound Resulting in AV Fistula and High-Output Heart Failure.

Journal Article Case Rep Cardiol · 2013 A 54-year-old African American male with no medical history presented to an urgent care clinic with signs and symptoms of new-onset congestive heart failure. There was an initial concern for congestive heart failure secondary to an ischemic etiology as an ... Full text Link to item Cite

Interventional Treatment of Hypertension: A New Paradigm

Journal Article Current Cardiology Reports · 2013 Cite

Temporal trends and geographic variation of lower-extremity amputation in patients with peripheral artery disease: results from U.S. Medicare 2000-2008.

Journal Article J Am Coll Cardiol · November 20, 2012 OBJECTIVES: This study sought to characterize temporal trends, patient-specific factors, and geographic variation associated with amputation in patients with lower-extremity peripheral artery disease (LE PAD) during the study period. BACKGROUND: Amputation ... Full text Link to item Cite

Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains.

Journal Article Circulation · September 11, 2012 BACKGROUND: Patients with peripheral artery disease (PAD) are at high risk of cardiovascular events and benefit from aggressive secondary prevention; however, changes in the use of cardioprotective medications after incident diagnosis of PAD have not been ... Full text Link to item Cite

"What the eyes don't see, the heart doesn't grieve over": epidemiology and risk factors for bloodstream infections following cardiac catheterization.

Journal Article Infect Control Hosp Epidemiol · August 2012 No standard definition exists for surveillance and characterization of the epidemiology of bloodstream infections (BSIs) after cardiac catheterization (CC) procedures. We proposed a novel case definition and determined the epidemiology and risk factors of ... Full text Link to item Cite

Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training.

Journal Article Vasc Med · April 2012 The aims of this study were twofold: (1) to identify whether peripheral artery disease (PAD) patients had increased muscle concentration of angiogenic VEGF-A, anti-angiogenic VEGF₁₆₅b or VEGF receptor 1 (VEGF-R1) when compared with control subjects, and (2 ... Full text Link to item Cite

Angiogenesis in skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patients.

Journal Article Arterioscler Thromb Vasc Biol · November 2011 OBJECTIVE: Peripheral artery disease (PAD) is characterized by impaired blood flow to the lower extremities, causing claudication and exercise intolerance. The mechanism(s) by which exercise training improves functional capacity is not understood. This stu ... Full text Link to item Cite

Trends in the use of diagnostic coronary angiography, percutaneous coronary intervention, and coronary artery bypass graft surgery across North Carolina.

Journal Article Am Heart J · November 2011 BACKGROUND: Although variation in use of invasive coronary procedures has been shown, the relationship between invasive diagnostic cardiac catheterization (Cath) and subsequent revascularization with percutaneous coronary intervention (PCI) or coronary art ... Full text Link to item Cite

Effect of peripheral arterial disease on functional and clinical outcomes in patients with heart failure (from HF-ACTION).

Journal Article Am J Cardiol · August 1, 2011 Patients with peripheral arterial disease (PAD) have lower functional capacity and worse clinical outcomes than age- and gender-matched patients. Few data exist on the relation of PAD to functional and clinical outcomes in patients with heart failure (HF). ... Full text Link to item Cite

Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease.

Journal Article J Appl Physiol (1985) · July 2011 The aim of this study was to determine if skeletal muscle capillary density is lower in patients with peripheral artery disease (PAD) and if capillary density relates to functional limitations. PAD patients with intermittent claudication (IC) have a decrea ... Full text Link to item Cite

A case of mistaken identity: persistent sciatic artery stenosis as a cause of critical limb ischemia.

Journal Article Catheter Cardiovasc Interv · February 1, 2011 Critical limb ischemia (CLI) is the most severe manifestation of peripheral arterial disease (PAD) and is defined as leg pain that occurs at rest, tissue ulceration, or gangrene. Initial diagnostic testing is often focused on localizing the level or site o ... Full text Link to item Cite

Is the Door-To-Balloon Metric a Pitfall to Improved Patient Outcomes?

Journal Article JOURNAL OF INVASIVE CARDIOLOGY · December 1, 2010 Link to item Cite

Erythropoietin activates mitochondrial biogenesis and couples red cell mass to mitochondrial mass in the heart.

Journal Article Circ Res · June 11, 2010 RATIONALE: Erythropoietin (EPO) is often administered to cardiac patients with anemia, particularly from chronic kidney disease, and stimulation of erythropoiesis may stabilize left ventricular and renal function by recruiting protective effects beyond the ... Full text Link to item Cite

Drug-eluting versus bare metal stenting in acute myocardial infarction. A clinical review.

Journal Article Minerva Cardioangiol · October 2009 Coronary heart disease is a leading cause of death around the world. The treatment of acute myocardial infarction has evolved with the advent of novel thrombolytic agents, anticoagulants, antiplatelets, and innovative percutaneous techniques. The developme ... Link to item Cite

Growth factors for therapeutic angiogenesis in peripheral arterial disease.

Journal Article Curr Opin Cardiol · September 2007 PURPOSE OF REVIEW: Peripheral arterial disease is a common disease that has few treatment options. Angiogenesis is defined as the growth of new blood vessels from preexisting vasculature. Therapeutic angiogenesis is an investigational method that uses vasc ... Full text Link to item Cite